Expanding populations are growing older. However, unlike old-world ways, modern society has devalued the elderly and their worth. This is evident in the U.S.’s massive workforce shortage dedicated to helping elderly patients with conditions like Alzheimer’s disease and dementia, despite being vastly funded.
Alzheimer’s disease rates in the U.S. are soaring exponentially. Currently, a new case of Alzheimer’s and other dementias occur every 66 seconds, and by 2050 the rate is expected to be 33 seconds. 10% of people over age 65 have Alzheimer’s dementia and two-thirds of them are women. Since 2000, deaths from Alzheimer’s disease have increased 89%, that’s to the point of 1 in 3 seniors dying with dementia.
The World Alzheimer Report studies health care for people with dementia. In 2016 they reported that healthcare services are overspecialized and need to be rebalanced in order to increase capacity and improve the coordination and integration of care. They also present economic models that show how to address the growing problem citing some .5 percent of healthcare expenditure is all that’s needed.
Alzheimer’s, like all types of dementia, is a neurodegenerative disease causing the progressive death of brain cells, impairing memory, communication and language skills, concentration, reasoning, and visual perception, among other functions. Brain cells of the hippocampal region are often the first to be damaged by the disease, which is why memory loss is one of the earliest symptoms of Alzheimer’s.
Build up of proteins and other substances in and around brain cells make it hard for them to stay healthy. As result neurons dissociate, brain matter shrinks, and the atypical behavior of dementia is shown, such as memory loss and confusion.
Recent studies have changed the direction of Alzheimer’s research. While it’s still debatable, new research points to mitochondria in the brain that begin to dysfunction, as we get older. Mutations of mitochondrial DNA cause them to produce destructive free radicals whose oxidative activity destroys neurons. Research is showing that Tau protein accumulating in the brain may be triggering mitochondrial distribution deficits.
Alzheimer’s Disease is an incurable disorder in the brain that severely degrades abilities of memory, self-care, and quality of life. Those suffering dementia, and their caretakers are experiencing major physical, emotional, and economic burdens.
There is no cure for the disease and current medications can only slow down the progression of the disease. Ideally, a preventative approach is best at combating this growing problem in population. Diet, exercise, and lifestyle have been proven to be key factors in maintaining optimum health in the brain and body as we age.
The most common medications for Alzheimer’s disease are Cholinesterase Inhibitors that can cause a barrage of unwanted side effects. Most Alzheimer’s medications in other countries were removed shortly after hitting market due to people dying so frequently after beginning use. It's vital to note that no one’s condition is improving from these medications.
Out of all the Alzheimer’s drugs tested between 2002 and 2012, 99.6% of them failed in clinical trials. Despite countless years of failed studies, [Big Pharma] continues to fund research into synthetic compounds, and companies such as Merck & Co. and Eli Lilly & Co. have plans to cash in on the potentially $30 billion Alzheimer’s market by releasing 35 new drugs over the next few years. Current research shows there hasn’t been much improvement in the new Alzheimer’s medications.
Various clinical studies over the years have causally linked THC to a slowed progression of dementia. One connection is that THC reduces amyloid protein buildup in the brain. Recent research indicates that cannabinoids exhibit [pleiotropic activity], targeting many processes that play key roles in Alzheimer’s disease.
The cannabinoids and terpenes found in medical marijuana have proven to help Alzheimer’s patients by increasing tau protein processing and reducing brain inflammation. The compounds in cannabis also target excitotoxicity, mitochondrial dysfunction, and oxidative stress due to dementia. Further research into cannabis’ neuroprotective properties could result in safe medicines for hard to treat neurological disorders such as Alzheimer’s.
Medical marijuana has also been shown to help manage the changes in psychological and physiological behavior typical of Alzheimer’s because of its ability to bind to [receptors] in the endocannabinoid system, modulating feelings of anxiety, depression, hunger, and many more.
Marijuana may help prevent early onset of dementia, and it has helped many people find relief from associated symptoms of the disease, but there is still no cure even if Big Pharma promises they’ve found it. The following list of High CBD and Hybrid Strains may be helpful in preventing the disease and managing acute and chronic symptoms.
· [[13 Dawgs]]
· [[Afternoon Delight]]
· [[Alien Reunion]]
· [[Blue Bastard]]
· [[Blueberry AK]]
· [[Blueberry Lambsbread]]
· [[Chunky Diesel]]
· [[G Stik “Orange”]]
· [[Grand Hindu]]
· [[Green Haze]]
· [[Green Hornet]]
· [[Green Monster]]
· [[Honey Boo Boo]]
· [[Kali Dog]]
· [[Kill Bill]]